The deal will enable customers in India, Bangladesh and Sri Lanka to access Novo Nordisk's range of FEF Quats
Novo Nordisk Pharmatech A/S has entered into an agreement with Signet Chemical Corporation for the distribution of its pharmaceutical range of quaternary ammonium compounds (FEF Quats) to the healthcare industry in India, Bangladesh and Sri Lanka.
Mr Shah, Managing director of Signet commented on this new collaboration: “We are pleased to be associated with Novo Nordisk Pharmatech which is the leading supplier of Quats to the pharmaceutical and biopharmaceutical markets. Novo Nordisk Pharmatech’s FeF Quats complement our existing portfolio of excipients used especially for ophthalmic, nasal and topical dosage forms”.
Novo Nordisk Pharmatech A/S manufactures Quats (Benzalkonium Chloride, Cetrimide and Cetyl Trimethyl Ammonium Bromide (CTAB), including customised grade, in accordance with cGMP (ICH Q7) for active pharmaceutical ingredients, which is the highest available quality standard.
Its products comply with the latest pharmacopoeial standards as they are extensively supported by CEPs, DMFs, and a comprehensive package of regulatory and quality assurance documents. Its manufacturing site in Denmark is audited by the Danish Medicines Agency and US FDA.
“We are very happy to work with Signet as our distribution partner for pharmaceuticals. Novo Nordisk Pharmatech’s FeF Quats products fit perfectly with Signet’s wide range of excipients enabling the customers to take advantage of these synergies. We wish to give the best service to our customers and the local pharma team of Signet are experts in working with customers to support their product development” says Steve Profit, Sales & Marketing Director at Novo Nordisk Pharmatech A/S.
Signet is one of India’s leading pharmaceutical excipient distributor company, offering a broad range of excipients under one crest. Founded in 1986, Signet Chemical Corporation is a pioneer in the excipients business in India.